Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy of Regorafenib as Maintenance Therapy in Non-adipocytic Soft Tissue Sarcoma Having Received First-line Doxorubicin-based Chemotherapy

NCT03793361 is registered in ClinicalTrials.gov with Centre Oscar Lambret as lead sponsor.

NCT NCT03793361
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03793361 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy of Regorafenib as Maintenance Therapy in Non-adipocytic Soft Tissue Sarcoma Having Received First-line Doxorubicin-based Chemotherapy
Lead sponsor
Centre Oscar Lambret
Phase
Phase 2
Overall status
Completed
Start date
May 15, 2019
Completion date
September 26, 2024
Enrollment
127 (actual)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic soft tissue sarcoma